- Findings from OCEANIC-STROKE, including the main results and a prespecified subgroup analysis, will be presented for the first time during two late-breaking sessions at the International Stroke Conference 2026
- Asundexian is an investigational once daily, oral Factor XIa (FXIa) inhibitor
Bayer today announced that the main results from its global, landmark Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention, will be presented during two late-breaking sessions at the upcoming American Stroke Association’s International Stroke Conference (ISC) 2026. The conference will be held February 4-6 in New Orleans, Louisiana, USA.
The research to be presented demonstrates the longstanding commitment of Bayer as a leader in cardiovascular and cerebrovascular medicine, advancing innovation in thrombosis prevention.
In November 2025, Bayer announced the OCEANIC-STROKE study met its primary efficacy and safety endpoints. OCEANIC-STROKE is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that enrolled over 12,300 patients.
Bayer late-breaking presentations on the Phase III study OCEANIC-STROKE at ISC 2026 include:
Late Breaker: Factor XIa Inhibition with Asundexian in Acute Non-Cardioembolic Stroke or High-Risk Transient Ischemic Attack: Primary Results of the OCEANIC-STROKE Trial
- Presenter: Mike Sharma, MD, McMaster University, Population Health Research Institute (PHRI)
- ISC invited symposium
- Thursday, February 5, 2026; 11:15 a.m. – 11:27 a.m. CST
- Main Event Late Breaking Science Trials, Hall D
Thursday Main Event Late-Breaking Science Trials: Q&A (Fireside Chat)
- Thursday, February 5, 2026; 2:30 p.m. – 3:30 p.m. CST
- Room 220-222
Late Breaker: Qualifying Ischemic Stroke Subtypes and Response to Asundexian: Prespecified Secondary Analysis of the OCEANIC-STROKE Trial
- Presenter: Ashkan Shoamanesh, MD, McMaster University
- Beyond the plenary: Deeper Dives into OCEANIC-STROKE, CREST-2 and FASTEST (Late-breaking Science Oral Abstract III)
- Thursday, February 5, 2026; 3:45 p.m. – 3:55 p.m. CST
- Main Event Late Breaking Science Trials, Hall D
To view the complete program, please visit the International Stroke Conference website.
Asundexian is an investigational agent and has not been approved by any health authority for use in any country for any indication.
Discover the latest trends and insights—explore the Business Insight Journal for up-to-date strategies and industry breakthroughs!
